caribou biosciences inc - CRBU
CRBU
Close Chg Chg %
1.66 0.06 3.61%
Closed Market
1.72
+0.06 (3.61%)
Volume: 333.00K
Last Updated:
Dec 24, 2025, 1:00 PM EDT
Company Overview: caribou biosciences inc - CRBU
CRBU Key Data
| Open $1.65 | Day Range 1.64 - 1.73 |
| 52 Week Range 0.66 - 3.53 | Market Cap $155.16M |
| Shares Outstanding 93.47M | Public Float 82.78M |
| Beta 2.60 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.70 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 942.02K |
CRBU Performance
| 1 Week | 2.38% | ||
| 1 Month | -11.34% | ||
| 3 Months | -19.25% | ||
| 1 Year | 2.99% | ||
| 5 Years | N/A |
CRBU Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About caribou biosciences inc - CRBU
Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.
CRBU At a Glance
Caribou Biosciences, Inc.
2929 7th Street
Berkeley, California 94710
| Phone | 1-510-982-6030 | Revenue | 9.99M | |
| Industry | Biotechnology | Net Income | -149,105,000.00 | |
| Sector | Health Technology | Employees | 147 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
CRBU Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 14.369 |
| Price to Book Ratio | 0.581 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.242 |
| Enterprise Value to Sales | -3.945 |
| Total Debt to Enterprise Value | -0.672 |
CRBU Efficiency
| Revenue/Employee | 67,986.395 |
| Income Per Employee | -1,014,319.728 |
| Receivables Turnover | 3.074 |
| Total Asset Turnover | 0.026 |
CRBU Liquidity
| Current Ratio | 7.157 |
| Quick Ratio | 7.157 |
| Cash Ratio | 6.836 |
CRBU Profitability
| Gross Margin | 60.706 |
| Operating Margin | -1,667.16 |
| Pretax Margin | -1,492.035 |
| Net Margin | -1,491.945 |
| Return on Assets | -39.145 |
| Return on Equity | -47.994 |
| Return on Total Capital | -53.355 |
| Return on Invested Capital | -44.355 |
CRBU Capital Structure
| Total Debt to Total Equity | 10.478 |
| Total Debt to Total Capital | 9.484 |
| Total Debt to Total Assets | 8.261 |
| Long-Term Debt to Equity | 9.907 |
| Long-Term Debt to Total Capital | 8.968 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Caribou Biosciences Inc - CRBU
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 9.60M | 13.85M | 34.48M | 9.99M | |
Sales Growth
| -22.35% | +44.31% | +148.91% | -71.01% | |
Cost of Goods Sold (COGS) incl D&A
| 984.00K | 3.64M | 3.52M | 3.93M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 984.00K | 3.64M | 3.52M | 3.93M | |
Depreciation
| 984.00K | 3.64M | 3.52M | 3.93M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | +270.02% | -3.19% | +11.40% | |
Gross Income
| 8.61M | 10.21M | 30.95M | 6.07M | |
Gross Income Growth
| - | +18.53% | +203.15% | -80.40% | |
Gross Profit Margin
| +89.75% | +73.71% | +89.78% | +60.71% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 75.59M | 116.61M | 147.01M | 172.68M | |
Research & Development
| 52.26M | 82.23M | 112.08M | 130.15M | |
Other SG&A
| 23.34M | 34.38M | 34.94M | 42.53M | |
SGA Growth
| +58.86% | +54.26% | +26.07% | +17.46% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (158.00K) | (2.30M) | 1.29M | (2.15M) | |
EBIT after Unusual Expense
| (66.82M) | (104.10M) | (117.35M) | (164.46M) | |
Non Operating Income/Expense
| 227.00K | 4.75M | 15.48M | 15.35M | |
Non-Operating Interest Income
| - | 148.00K | 4.60M | 10.70M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 8.00K | - |
Interest Expense Growth
| - | - | - | -60.00% | - |
Gross Interest Expense
| - | - | - | 8.00K | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (66.60M) | (99.35M) | (101.88M) | (149.11M) | |
Pretax Income Growth
| -84.36% | -49.17% | -2.54% | -46.37% | |
Pretax Margin
| -693.92% | -717.28% | -295.49% | -1,492.04% | |
Income Tax
| 321.00K | 70.00K | 193.00K | (9.00K) | |
Income Tax - Current - Domestic
| 1.00K | 165.00K | 15.00K | 1.00K | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 320.00K | (95.00K) | 178.00K | (10.00K) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (66.92M) | (99.42M) | (102.07M) | (149.10M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (66.92M) | (99.42M) | (102.07M) | (149.10M) | |
Net Income Growth
| -95.07% | -48.56% | -2.66% | -46.08% | |
Net Margin Growth
| -697.26% | -717.79% | -296.05% | -1,491.95% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (66.92M) | (99.42M) | (102.07M) | (149.10M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (66.92M) | (99.42M) | (102.07M) | (149.10M) | |
EPS (Basic)
| -1.1105 | -1.6352 | -1.3829 | -1.6509 | |
EPS (Basic) Growth
| -94.11% | -47.25% | +15.43% | -19.38% | |
Basic Shares Outstanding
| 60.26M | 60.80M | 73.81M | 90.32M | |
EPS (Diluted)
| -1.1105 | -1.6352 | -1.3829 | -1.6509 | |
EPS (Diluted) Growth
| -94.11% | -47.25% | +15.43% | -19.38% | |
Diluted Shares Outstanding
| 60.26M | 60.80M | 73.81M | 90.32M | |
EBITDA
| (66.00M) | (102.76M) | (112.53M) | (162.69M) | |
EBITDA Growth
| -87.36% | -55.71% | -9.51% | -44.57% | |
EBITDA Margin
| -687.59% | -741.88% | -326.40% | -1,627.87% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 11.00 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.323 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -1.594 | |
| Last Quarter’s Earnings | -0.30 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.65 | Next Fiscal Year Estimate | -1.43 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 2 | 7 | 7 |
| Mean Estimate | -0.32 | -0.33 | -1.59 | -1.43 |
| High Estimates | -0.30 | -0.30 | -1.50 | -0.99 |
| Low Estimate | -0.36 | -0.36 | -1.65 | -1.81 |
| Coefficient of Variance | -6.62 | -12.86 | -3.97 | -19.11 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 7 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Caribou Biosciences Inc - CRBU
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Caribou Biosciences Inc - CRBU
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 24, 2025 | Dara Richardson-Heron Director | 40,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Tina Albertson Chief Medical Officer | 66,137 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Nancy C. Whiting Director | 40,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Ran Zheng Director | 40,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | David L. Johnson Director | 40,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Natalie R. Sacks Director | 40,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Rachel E. Haurwitz President and CEO; Director | 618,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Rachel E. Haurwitz President and CEO; Director | 295,450 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Steven B. Kanner Chief Scientific Officer | 170,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Steven B. Kanner Chief Scientific Officer | 431,556 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 582,600.60 |
| Feb 24, 2025 | Steven B. Kanner Chief Scientific Officer | 435,120 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Andrew L. Guggenhime Director | 40,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Ruhi Khan Chief Business Officer | 170,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Ruhi Khan Chief Business Officer | 66,936 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 90,363.60 |
| Feb 24, 2025 | Ruhi Khan Chief Business Officer | 70,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Timothy P. Kelly Chief Technology Officer | 170,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Timothy P. Kelly Chief Technology Officer | 37,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Scott N. Braunstein Director | 40,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Barbara G. McClung Chief Legal Officer | 170,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 24, 2025 | Barbara G. McClung Chief Legal Officer | 443,502 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.35 per share | 598,727.70 |